Bristol Myers Squibb

BMS, Synairgen regroup after trials miss primary endpoints

Blockbusters, Bristol Myers Squibb, Business, Clinical Trials, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, Metastatic Urothelial Carcinoma (mUC), R&D, R&D, Therapeutics

Bristol Myers Squibb shared the news that the company’s Phase III clinical trial investigating the safety and efficacy of Opdivo and Yervoy combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma failed to meet the predetermined primary endpoint. A posthoc analysis was shared by Synairgen suggesting that, despite SNG001 failing to meet the primary endpoint of patient recovery and subsequent hospital discharge in a Phase III study for patients hospitalized with COVID-19 who required supplemental oxygen treatment, they may benefit from receiving the treatment.

May 16, 2022/by BioSpace

BridgeBio augments comeback week with sale of priority review voucher

Bristol Myers Squibb, Business, FDA, Layoffs, Molybdenum cofactor deficiency (MoCD) Type A, PDUFA, Priority Review, Priority Review Status, Priority Review Voucher, Rare Diseases, Rare Pediatric Disease Priority Review Voucher, Sales, Therapeutics

One day after BridgeBio Pharma struck a nearly $1 billion oncology pact with Bristol Myers Squibb, the California-based company announced plans to sell a priority review voucher received in February.

May 13, 2022/by BioSpace

BMS & BridgeBio team up in nearly $1B oncology pact

Biopharma Companies, BioSpace, Bristol Myers Squibb, Business, Cancer, Collaborations, Commercialization, Deals, Licensing, MD Anderson Cancer Center, Oncology, R&D, R&D, SHP2 inhibitors, Tumors

BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.

May 12, 2022/by BioSpace

Reuters

Blow to Roche’s cancer immunotherapy prospects as 2nd trial fails

Advanced lung cancer, Advanced Non-Small Cell Lung Cancer, Bristol Myers Squibb, Business, Clinical Trials, Gilead, Immunotherapies, Merck, Non-Small Cell Lung Cancer, R&D, R&D, Roche

Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.

May 11, 2022/by Reuters Health

BMS and Merck KGaA Buy Big Into Amphista’s Protein Degradation Platform

Bristol Myers Squibb, Business, Deals, Partnerships, Protein degradation

Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. On May 4, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.

May 4, 2022/by BioSpace

FDA approves Bristol Myers’ oral heart disease drug

Approvals, Boxed Warning, Bristol Myers Squibb, Cardiac Arrest, Cardiac myosin inhibitors, FDA, Genetic Inflammatory Conditions, Heart Disease, Heart Muscles, Hypertrophic cardiomyopathy (HCM), Left Ventricular Ejection Fraction (LVEF), Oral Therapy, Therapeutics, Wholesale Acquisition Cost

The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.

April 28, 2022/by Reuters Health

Nektar Cuts 70% of Workforce on Heels of BMS-Partnered Collapse

Autoimmune Disease, Bladder Cancer, Blockbusters, Bristol Myers Squibb, Business, Cancer, CAR-T Therapy, Checkpoint Inhibitors, Clinical Trials, Collaborations, Job Cuts, Melanoma, Product Pipeline, R&D, Renal Cell Carcinoma (RCC), Reorganization

Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70 percent of the company’s workforce, only weeks after Bristol Myers Squibb abandoned its clinical collaboration program with Nektar on bladder cancer and renal cell carcinoma.

April 26, 2022/by BioSpace

Nektar stops clinical trials for key cancer drug, shares tumble

Bladder Cancer, Blockbusters, Bristol Myers Squibb, Business, Clinical Trials, Melanoma, Metastatic Urothelial Carcinoma (mUC), Partnerships, R&D, Renal Cell Carcinoma (RCC), Shares, Therapeutics

Nektar Therapeutics said on April 14 the company had stopped all clinical trials involving the drug developer’s key cancer drug bempegaldesleukin following its failure in multiple studies, dragging Nektar shares down 23% in after-market trading.

April 14, 2022/by Andrew Humphreys

BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision

Bristol Myers Squibb, Cardiac myosin inhibitors, Cardiovascular Disease, Clinical Trials, Hypertrophic cardiomyopathy (HCM), R&D, R&D, Research & Development

Bristol Myers Squibb announced results from an extended study to evaluate the long-term effects of taking the cardiovascular drug mavacamten.

April 4, 2022/by BioSpace

Roche and BMS Leveraging AI for Solid Tumor Treatment

Artificial Intelligence, Bristol Myers Squibb, Business, Collaborations, Digital, Partnerships, Pathology, R&D, Roche, Solid Tumors

Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.

March 25, 2022/by BioSpace